Skip to main content

A rare presentation of central pontine myelinolysis secondary to hyperglycaemia

Abstract

Background

Central pontine myelinolysis (CPM) is a rare demyelinating disorder caused by the loss of myelin in the center of the basis pontis. CPM typically occurs with rapid correction of severe chronic hyponatremia and subsequent disturbances in serum osmolality. Although hyperglycaemia is recognized as a pathogenetic factor in serum osmolality fluctuations, CPM is rarely seen in the context of diabetes.

Case presentation

A 66-year-old Chinese male presented with a history of gait imbalance, mild slurred speech and dysphagia for two weeks. MRI showed the mass lesions in the brainstem, and laboratory examinations showed high blood glucose and HbA1c, as well as increased serum osmolality. The patient was diagnosed with CPM secondary to hyperosmolar hyperglyceamia and received insulin treatment as well as supportive therapy. After six weeks of followup, the patient had fully recovered to a normal state.

Conclusion

CPM is a potentially fatal neurological condition and can occur in uncontrolled diabetes mellitus. Early diagnosis and timely treatment are crucial for improving the prognosis.

Peer Review reports

Background

Central pontine myelinolysis (CPM) is a demyelinating disorder caused by the loss of myelin in the centre of the basis pontis; this disorder presents clinically with quadriparesis, dysarthria, ophthalmoplegia, ataxia, psychosis, seizures, and altered mental status [1,2,3,4,5,6]. CPM was initially described in the patients with malnutrition or alcoholism and typically occurred after rapid correction of severe and chronic hyponatremia [7]. Other pathogenetic conditions, including prolonged diuretic use, burns and liver transplantation, have also been recognized as risk factors for the developmemt of CPM [8, 9]. While hyperglycaemia is a potential cause of the disturbance in serum osmolality, CPM rarely occurs secondary to the management of diabetes mellitus, especially in uncontrolled diabetes mellitus. Although there is no effective treatment for CPM, recent results suggest that the early diagnosis and improved intensive care treatment are closely associated with improved outcomes [10]. In the present case report, the patient developed CPM following uncontrolled hyperglycaemia in the absence of sodium abnormalities; he responded well to glucose control, recovering completely.

Case presentation

A 66-year-old Chinese male presented with a two-week history of gait imbalance, mild slurred speech and dysphagia. One week previously, he had been admitted to the local hospital, and investigations showed a normal brain computed tomography (CT) and a significant increase in serum blood glucose (22.6 mmol/L). The patient was diagnosed with 2 diabetes mellitus and managed with an insulin regimen and aspirin. Due to noncompliance with the drug therapy regimen, the patient’s symptoms progressively aggravated over the ensuing week. He did not have alcohol use disorder, and there no history of any significant chronic illness or surgery. Physical examination revealed that the patient was conscious and oriented to time, place and person, and his cranial nerves, motor strength and deep tendon reflexes were normal. He had dysarthria, mild dysphagia, and ataxia with bilateral dysmetria.

Laboratory evaluation revealed the following values: random blood sugar 27.59 mmol/L, haemoglobin A1c 15%, sodium137 mmol/L, potassium 4.37 mmol/L, urea 8.49 mmol/L, and creatinine 104 µmol/L. The measured serum osmolality was 319 mmol/L. Cerebrospinal fluid analysis showed normal biochemistry and cell counts along with a negative microbiological workup. Magnetic resonance imaging (MRI) showed a sharply defined, symmetrically shaped lesion in the central pons with decreased signal intensity on T1 and increased signal intensity on T2 and fluid-attenuated inversion recovery (FLAIR)-weight imaging (Fig. 1).

Fig. 1
figure 1

MR images of the brain. A T1-weighted imaging showing a mildly hypointense lesion in the central pons; (B, D) T2 and (C) FLAIR-weight imaging demonstrating a hyperintense lesion in the same location

A diagnosis of CPM secondary to hyperglycaemia was made, and the management of a sliding-scale subcutaneous insulin regimen was initiated. According to sliding-scale insulin therapy, the initial insulin dose was set as 12 IU. The total dose of insulin was 0.6 IU/Kg/d, where in the basal dose and the premeal bolus account for 50% of the total dose each. For three premeal bolus, the insulin dose account for 40%, 30%, and 30%, respectively. The insulin dose was adjusted dynamically according to the results of the glucose monitoring. The glucose decreased smoothly and finally attained glycemic control target. The physical rehabilitation was prescribed for pseudobulbar palsy. Gradual improvement in the patient’s gait imbalance, slurred speech, and dysphagia was noted over the ensuing week. He was discharged at the end of the second week, and no changes were evident on repeat MRI. The patient’s symptoms, however, were further recovered. After six weeks of follow-up, the patient had fully recovered to a normal state.

Discussion

CPM is an acquired demyelinating lesion of the basis pontis associated with various clinical circumstances, including alcoholism, malnutrition, prolonged diuretic use, burns and liver transplantatipon [11,12,13,14,15]. The rapid correction of severe chronic hyponatremia is recognized as a common pathogenic factor triggering osmotic stress and subsequent demyelination in the central pons [16, 17]. Osmotic stress impairs the blood–brain barrier (BBB), leading to disruption of the BBB and osmotic demyelination of vulnerable cells in the brain. Pathologically, CPM is characterized by the loss and destruction of myelin sheaths, while neuronal cell bodies and axons are preserved [5]. The central pons is hightly susceptible to osmotic stress due to the rich in admixture of grey and white matter elements [11]. Demyelinating lesions can also occur at extrapontine sites including the basal ganglia, cerebellum, internal capsule and thalamus under the osmotic stress conditions, in a condition referred to as extrapontine myelinolysis (EPM); thus the syndrome consisting of CPM and EPM is termed osmotic demyelination syndrome (ODS) [16, 18]. The majority of the documented CPM cases are described secondary to disturbances in sodium homeostasis, especially in the rapid correction of severe chronic hyponatremia. However, several cases of CPM have been reported in association with the hyperosmolar hyperglycaemic state (HHS), and as a complication following by the management of HHS [19, 20]. Recently, reports have described rare cases of CPM as a complication of undiagnosed or untreated diabetes in the absence of abnormal serum sodium concentrations [2, 21]. Similar to the patients in thoses reports, our patient presented with hyperglycaemia alone and was not being treated for hyperosmolar hyperglycaemia. Hyperosmolar hyperglycaemia is associated with the changes in osmolality and the occurrence of ODS. Thus, our findings support the conclusion that the disturbance of serum osmolality is a central event in the pathogenesis of CPM and is responsible for the demyelination in the central pons, regardless of serum sodium levels.

Clinical manifestations of CPM vary based on the brain region involved and typically include spastic quadriparesis, dysarthria, dysphagia, sensory alterations, and encephalopathy of various degrees as well as ‘locked-in syndrome’in severe cases [1, 3, 5, 22]. Our patient developed a predominant clinical manifestation of ataxia along with mild dysphagia, caused by injury to corticocerebellar and corticobulbar fibres, respectively. The diagnosis of CPM depends on clinical manifestations and a characteristic radiographic appearance. The typical CPM lesion is described as a symmetric, sharply demarcated focus in the basis pontis. CT is usually normal for several days to two weeks, after which the typical hypodense lesions may be evident in the basis pontis [5]. Consistent with these reports, the brain CT of our patient was normal more than a week after the onset of symptoms. Magnetic resonance imaging (MRI) is more sensitive and reliable than CT for the diagnosis of CPM. Characteristic.

CPM lesions, located in the basis pontis, are hyperintense on T2-weighted imaging, and hypointense on T1-weighted imaging [23]. There is no effective treatment available for CPM, and the condition is managed mainly through supportive treatment. A few reports of the administration of intravenous immunoglobulin, plasmapheresis exchange or thyrotropin-releasing hormone indicate a positive effect on recovery from CPM. Limited sample sizes, however, leave the effectiveness of these therapeutic methods uncertain [16]. In the current case report, the patient was completely recovered after his blood sugar level controlled. Based on sereral previous reports and our case, timely diagnosis and treatment seem to improve recovery from hyperglycaemia-related CPM [2, 24,25,26].

Conclusion

CPM is a potential complication of uncontrolled diabetes mellitus in the absence of sodium abnormalities, and MRI examination is needed to provide early clues for the diagnosis and timely treatment of this disease. Control of blood glucose should be emphasized in patients with diabetes mellitus to prevent the development of CPM.

Availability of data and materials

All relevant data are included in the manuscript.

Abbreviations

CPM:

Central pontine myelinolysis

BBB:

Blood–brain barrier

EPM:

Extrapontine myelinolysis

ODS:

Osmotic demyelination syndrome

HHS:

Hyperosmolar hyperglycaemia state

References

  1. Lee TM, Cheung CC, Lau EY, Mak A, Li LS. Cognitive and emotional dysfunction after central pontine myelinolysis. Behav Neurol. 2003;14(3–4):103–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saini M, Mamauag MJ, Singh R. Central pontine myelinolysis: a rare presentation secondary to hyperglycaemia. Singapore Med J. 2015;56(4):e71-73.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Feng XM, Zhao T, Zhou CK, Liu JY. Psychiatric symptoms and limb tremors associated with central pontine myelinolysis: A case of alcoholism without hyponatremia. Exp Ther Med. 2016;12(5):3485–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chang KY, Lee IH, Kim GJ, Cho K, Park HS, Kim HW. Plasma exchange successfully treats central pontine myelinolysis after acute hypernatremia from intravenous sodium bicarbonate therapy. BMC Nephrol. 2014;15:56.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hurley RA, Filley CM, Taber KH. Central pontine myelinolysis: a metabolic disorder of myelin. J Neuropsychiatry Clin Neurosci. 2011;23(4):369–74.

    Article  PubMed  Google Scholar 

  6. Haynes HR, Gallagher PJ, Cordaro A, Likeman M, Love S. A case of chronic asymptomatic central pontine myelinolysis with histological evidence of remyelination. Forensic Sci Med Pathol. 2018;14(1):106–8.

    Article  PubMed  Google Scholar 

  7. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry. 1959;81(2):154–72.

    Article  CAS  PubMed  Google Scholar 

  8. Lupato A, Fazio P, Fainardi E, Cesnik E, Casetta I, Granieri E. A case of asymptomatic pontine myelinolysis. Neurol Sci. 2010;31(3):361–4.

    Article  PubMed  Google Scholar 

  9. Abbott R, Silber E, Felber J, Ekpo E. Osmotic demyelination syndrome. BMJ. 2005;331(7520):829–30.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kleinschmidt-Demasters BK, Rojiani AM, Filley CM. Central and extrapontine myelinolysis: then… and now. J Neuropathol Exp Neurol. 2006;65(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  11. Esforzado N, Poch E, Cases A, Cardenal C, Lopez-Pedret J, Revert L. Central pontine myelinolysis secondary to frequent and rapid shifts in plasma glucose in a diabetic haemodialysis patient. Nephrol Dial Transplant. 1993;8(7):644–6.

    CAS  PubMed  Google Scholar 

  12. McKee AC, Winkelman MD, Banker BQ. Central pontine myelinolysis in severely burned patients: relationship to serum hyperosmolality. Neurology. 1988;38(8):1211–7.

    Article  CAS  PubMed  Google Scholar 

  13. Sivaswamy L, Karia S. Extrapontine myelinolysis in a 4 year old with diabetic ketoacidosis. Eur J Paediatr Neurol. 2007;11(6):389–93.

    Article  PubMed  Google Scholar 

  14. Lampl C, Yazdi K. Central pontine myelinolysis. Eur Neurol. 2002;47(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  15. Fleming JD, Babu S. Images in clinical medicine. Central pontine myelinolysis. N Engl J Med. 2008;359(23):e29.

    Article  PubMed  Google Scholar 

  16. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 3:iii22-28.

    CAS  PubMed  Google Scholar 

  17. Huang WY, Weng WC, Peng TI, Ro LS, Yang CW, Chen KH. Central pontine and extrapontine myelinolysis after rapid correction of hyponatremia by hemodialysis in a uremic patient. Ren Fail. 2007;29(5):635–8.

    Article  PubMed  Google Scholar 

  18. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(Pt 4):859–76.

    Article  PubMed  Google Scholar 

  19. O’Malley G, Moran C, Draman MS, King T, Smith D, Thompson CJ, Agha A. Central pontine myelinolysis complicating treatment of the hyperglycaemic hyperosmolar state. Ann Clin Biochem. 2008;45(Pt 4):440–3.

    Article  PubMed  Google Scholar 

  20. Burns JD, Kosa SC, Wijdicks EF. Central pontine myelinolysis in a patient with hyperosmolar hyperglycemia and consistently normal serum sodium. Neurocrit Care. 2009;11(2):251–4.

    Article  PubMed  Google Scholar 

  21. Mir WAY, Shrestha DB, Aryal BB, Reddy VK, Yadullahi MAA. Central pontine myelinolysis secondary to hyperglycemia in a young patient. Cureus. 2021;13(10):e18495.

    PubMed  PubMed Central  Google Scholar 

  22. Sohn MK, Nam JH. Locked-in syndrome due to central pontine myelinolysis: case report. Ann Rehabil Med. 2014;38(5):702–6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rippe DJ, Edwards MK, D’Amour PG, Holden RW, Roos KL. MR imaging of central pontine myelinolysis. J Comput Assist Tomogr. 1987;11(4):724–6.

    Article  CAS  PubMed  Google Scholar 

  24. Corps Fernandez D, Terrero Carpio R, Escolar Escamilla E, Pinel Gonzalez A. Subacute central pontine myelinolysis secondary to hyperglycaemia. Neurologia 2017.

  25. Pliquett RU, Noll A, Ibe R, Katz A, Ackmann C, Schreiber A, Girndt M. Hyperglycemia-related central pontine demyelinization after a binge-eating attack in a patient with type-2 diabetes: a case report. BMC Endocr Disord. 2018;18(1):18.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ramineni KK, Reddy KM, Kumar Prusthi BS, Jakkani RK. Pontine myelinolysis as the presenting complication of Type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018;22(3):434–5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable

Author information

Authors and Affiliations

Authors

Contributions

WPS and DWL designed the studies, YDW and SG collected the preclinical and clincal data and helped to finalize the manuscript, YFW also gathered clinical data, DWL reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Da-Wei Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The patient’s written consent for publication of his case history, including the use of all medical details and all radiographic images, was obtained.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, WP., Wang, YD., Gao, S. et al. A rare presentation of central pontine myelinolysis secondary to hyperglycaemia. BMC Endocr Disord 23, 106 (2023). https://doi.org/10.1186/s12902-023-01361-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-023-01361-y

Keywords